Trial Profile
Double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of ABT-925 in subjects with acute exacerbation of schizophrenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 May 2011
Price :
$35
*
At a glance
- Drugs ABT 925 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 14 Dec 2007 Status changed from recruiting to discontinued according to ClinicalTrials.gov.
- 16 Apr 2007 New trial record.